Pure Global AI
NCT06154278Not yet recruiting

Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

Pilot Study to Evaluate Intrahepatic and Peripheral Responses to Small Interfering RNA, Imdusiran (AB-729), Among People With Chronic Hepatitis B
University of Maryland, BaltimorePhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Chronic Hepatitis B
Drug/Device/Intervention
Imdusiran (AB-729)
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Maryland, Baltimore
Timeline & enrollment
Phase
Phase 2
Start date
Dec 01, 2023
End date
Jul 01, 2026
Enrollment
10 participants
Primary outcome

Intrahepatic concentration of Imdusiran (AB-729)

Summary

The goal of this clinical trial is to learn about the action of Imdusiran (AB-729) in the
 liver of people with chronic hepatitis B. The main questions it aims to answer are:
 
 - how well is it working in the liver
 
 - how does Imdusiran affect the hepatitis B virus
 
 Participants will receive injections of Imdusiran, one injection every 8 weeks, for a total
 of 4 doses. They will also undergo 2 liver biopsies: one with the first dose of Imdusiran,
 and the second 8 weeks after the last dose of Imdusiran.

ICD-10 classifications
Acute hepatitis BChronic viral hepatitis B without delta-agentAcute delta-(super)infection in chronic hepatitis BChronic viral hepatitis B without delta-agent : other and unspecified phaseChronic viral hepatitis B without delta-agent : immune-tolerant phase
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06154278
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06154278 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Maryland, Baltimore and is currently Not yet recruiting. The study focuses on Chronic Hepatitis B. Target enrollment is 10 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.